Efficacy of Low-dose Olanzapine in Combination with Sertraline on Negative Symptoms and Psychosocial Functioning in Schizophrenia: A Randomized Controlled Trial


Cite item

Full Text

Abstract

Background:Evidence for the efficacy of a low dose of olanzapine (OLA) in combination with antidepressants has been limited and without positive trials in first-episode (FE) patients with schizophrenia (SCH). This study aimed to compare the efficacy in treating negative and depressive symptoms between those FE patients with SCH treated with a combination of OLA plus sertraline and those treated with OLA monotherapy.

Methods:One hundred and ninety-six first-episode and drug naïve patients with SCH were randomized to receive low-dose OLA (7.5-10 mg/day) combined with sertraline (50-100 mg/day) (OS group) or normal-dose OLA monotherapy (12.5-20 mg/day) (NO group). Clinical symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS), and the depressive symptoms were evaluated by the Hamilton Depression Scale (HAMD). Psychosocial functioning was assessed by the Personal and Social Performance Scale (PSP).

Results:In the intent-to-treat efficacy analysis, the OS group had greater decreases in negative and depressive symptoms (palp < 0.01) and a greater increase in PSP total score compared with the NO group (p < 0.01). Moreover, reductions in HAMD total score and PANSS negative subscore and sex were associated with the improvements in psychosocial functioning from baseline to week 24, after controlling for baseline psychosocial function, age, and onset age.

Conclusion:This study demonstrates that low-dose OLA in combination with sertraline had clinically meaningful improvements not only in the negative and depressive symptoms but also in psychosocial functioning in patients with FE-SCH, while not affecting positive symptoms.

About the authors

Meihong Xiu

Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School

Email: info@benthamscience.net

Lei Zhao

, Qingdao Mental Health Cente

Email: info@benthamscience.net

Qianqian Sun

, Qingdao Mental Health Cente

Email: info@benthamscience.net

Xiaoe Lang

Department of Psychiatry, First Hospital of Shanxi Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Kahn, R.S.; Sommer, I.E.; Murray, R.M.; Meyer-Lindenberg, A.; Weinberger, D.R.; Cannon, T.D.; O’Donovan, M.; Correll, C.U.; Kane, J.M.; van Os, J.; Insel, T.R. Schizophrenia. Nat. Rev. Dis. Primers, 2015, 1(1), 15067. doi: 10.1038/nrdp.2015.67 PMID: 27189524
  2. Salomon, J.A.; Haagsma, J.A.; Davis, A.; de Noordhout, C.M.; Polinder, S.; Havelaar, A.H.; Cassini, A.; Devleesschauwer, B.; Kretzschmar, M.; Speybroeck, N.; Murray, C.J.L.; Vos, T. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob. Health, 2015, 3(11), e712-e723. doi: 10.1016/S2214-109X(15)00069-8 PMID: 26475018
  3. Cheng, Z.; Yuan, Y.; Han, X.; Yang, L.; Cai, S.; Yang, F.; Lu, Z.; Wang, C.; Deng, H.; Zhao, J.; Xiang, Y.; Correll, C.U.; Yu, X. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. J. Psychopharmacol., 2019, 33(10), 1227-1236. doi: 10.1177/0269881119872193 PMID: 31487208
  4. Kahn, R.S.; Fleischhacker, W.W.; Boter, H.; Davidson, M.; Vergouwe, Y.; Keet, I.P.M.; Gheorghe, M.D.; Rybakowski, J.K.; Galderisi, S.; Libiger, J.; Hummer, M.; Dollfus, S.; López-Ibor, J.J.; Hranov, L.G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher-Rössler, A.; Grobbee, D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 2008, 371(9618), 1085-1097. doi: 10.1016/S0140-6736(08)60486-9 PMID: 18374841
  5. Haro, J.M.; Suarez, D.; Novick, D.; Brown, J.; Usall, J.; Naber, D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur. Neuropsychopharmacol., 2007, 17(4), 235-244. doi: 10.1016/j.euroneuro.2006.09.005 PMID: 17137759
  6. Kishimoto, T.; Hagi, K.; Nitta, M.; Kane, J.M.; Correll, C.U. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: A systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry, 2019, 18(2), 208-224. doi: 10.1002/wps.20632 PMID: 31059621
  7. Leucht, S.; Cipriani, A.; Spineli, L.; Mavridis, D.; Örey, D.; Richter, F.; Samara, M.; Barbui, C.; Engel, R.R.; Geddes, J.R.; Kissling, W.; Stapf, M.P.; Lässig, B.; Salanti, G.; Davis, J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 2013, 382(9896), 951-962. doi: 10.1016/S0140-6736(13)60733-3 PMID: 23810019
  8. Citrome, L.; McEvoy, J.P.; Todtenkopf, M.S.; McDonnell, D.; Weiden, P.J. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: The past, present, and future. Neuropsychiatr. Dis. Treat., 2019, 15, 2559-2569. doi: 10.2147/NDT.S209284 PMID: 31564881
  9. Meftah, A.M.; Deckler, E.; Citrome, L.; Kantrowitz, J.T. New discoveries for an old drug: A review of recent olanzapine research. Postgrad. Med., 2020, 132(1), 80-90. doi: 10.1080/00325481.2019.1701823 PMID: 31813311
  10. Bhana, N.; Foster, R.H.; Olney, R.; Plosker, G.L. Olanzapine. Drugs, 2001, 61(1), 111-161. doi: 10.2165/00003495-200161010-00011 PMID: 11217867
  11. Olanzapine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2012.
  12. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res., 1999, 35(1), 51-68. doi: 10.1016/S0920-9964(98)00105-4 PMID: 9988841
  13. Davis, J.M.; Chen, N.; Glick, I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry, 2003, 60(6), 553-564. doi: 10.1001/archpsyc.60.6.553 PMID: 12796218
  14. Buchanan, R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophr. Bull., 2007, 33(4), 1013-1022. doi: 10.1093/schbul/sbl057 PMID: 17099070
  15. Javitt, D.C. Management of negative symptoms of schizophrenia. Curr. Psychiatry Rep., 2001, 3(5), 413-417. doi: 10.1007/s11920-996-0036-9 PMID: 11559479
  16. Mäkinen, J.; Miettunen, J.; Isohanni, M.; Koponen, H. Negative symptoms in schizophrenia—A review. Nord. J. Psychiatry, 2008, 62(5), 334-341. doi: 10.1080/08039480801959307 PMID: 18752104
  17. González-Maeso, J.; Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci., 2009, 32(4), 225-232. doi: 10.1016/j.tins.2008.12.005 PMID: 19269047
  18. Singh, S.P.; Singh, V.; Kar, N.; Chan, K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br. J. Psychiatry, 2010, 197(3), 174-179. doi: 10.1192/bjp.bp.109.067710 PMID: 20807960
  19. Shi, H.; Xu, J.; Lang, X.; Wu, H.E.; Xiu, M.H.; Zhang, X.Y. Comparison of efficacy and safety between low-dose ziprasidone in combination with sertraline and ziprasidone monotherapy for treatment-resistant patients with acute exacerbation schizophrenia: A randomized controlled trial. Front. Pharmacol., 2022, 13, 863588. doi: 10.3389/fphar.2022.863588 PMID: 35559243
  20. Zhu, C.; Guan, X.; Wang, Y.; Liu, J.; Kosten, T.R.; Xiu, M.; Wu, F.; Zhang, X. Low-dose ziprasidone in combination with sertraline for first-episode drug-Naïve patients with schizophrenia: A randomized controlled trial. Neurotherapeutics, 2022, 19(3), 1037-1046. doi: 10.1007/s13311-022-01242-7 PMID: 35467271
  21. Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 1987, 13(2), 261-276. doi: 10.1093/schbul/13.2.261 PMID: 3616518
  22. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 1960, 23(1), 56-62. doi: 10.1136/jnnp.23.1.56 PMID: 14399272
  23. Guy, W. ECDEU Assessment Manual for Psychopharmacology; US Department of Health, Education, and Welfare, 1976, pp. 217-222.
  24. Morosini, P.L.; Magliano, L.; Brambilla, L.; Ugolini, S.; Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr. Scand., 2000, 101(4), 323-329. doi: 10.1111/j.1600-0447.2000.tb10933.x PMID: 10782554
  25. Choen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed; Lawrence Erlbaum Associates, 1988.
  26. Mulholland, C.; Lynch, G.; King, D.J.; Cooper, S.J. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J. Psychopharmacol., 2003, 17(1), 107-112. doi: 10.1177/0269881103017001713 PMID: 12680747
  27. Tollefson, G.D.; Birkett, M.A.; Kiesler, G.M.; Wood, A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry, 2001, 49(1), 52-63. doi: 10.1016/S0006-3223(00)01026-X PMID: 11163780
  28. Conley, R.R.; Kelly, D.L.; Gale, E.A. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res., 1998, 33(1-2), 95-101. doi: 10.1016/S0920-9964(98)00062-0 PMID: 9783349
  29. Volavka, J.; Czobor, P.; Sheitman, B.; Lindenmayer, J.P.; Citrome, L.; McEvoy, J.P.; Cooper, T.B.; Chakos, M.; Lieberman, J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 2002, 159(2), 255-262. doi: 10.1176/appi.ajp.159.2.255 PMID: 11823268
  30. Meyers, B.S.; Flint, A.J.; Rothschild, A.J.; Mulsant, B.H.; Whyte, E.M.; Peasley-Miklus, C.; Papademetriou, E.; Leon, A.C.; Heo, M. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD). Arch. Gen. Psychiatry, 2009, 66(8), 838-847. doi: 10.1001/archgenpsychiatry.2009.79 PMID: 19652123
  31. Popli, A.; Fuller, M.; Jaskiw, G. Sertraline and psychotic symptoms: A case series. Ann. Clin. Psychiatry, 1997, 9(1), 15-17. doi: 10.3109/10401239709147769 PMID: 9167832
  32. Richelson, E. Pharmacology of antidepressants characteristics of the ideal drug. Mayo Clin. Proc., 1994, 69(11), 1069-1081. doi: 10.1016/S0025-6196(12)61375-5 PMID: 7967761
  33. Kinon, B.J.; Ahl, J.; Stauffer, V.L.; Hill, A.L.; Buckley, P.F. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs, 2004, 18(9), 597-616. doi: 10.2165/00023210-200418090-00005 PMID: 15222776
  34. Sax, K.W.; Stephen, M.S.; Strakowski, P.K.; Vidya, H.U.; Scott, A.W.; Susan, L.M. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depressionbeijing huilongguan hospital. Br. J. Psychiatry, 2018, 168(1), 10.
  35. Vita, A.; Barlati, S. Recovery from schizophrenia. Curr. Opin. Psychiatry, 2018, 31(3), 246-255. doi: 10.1097/YCO.0000000000000407 PMID: 29474266
  36. Kossmann, C.; Heller, J.; Brüne, M.; Schulz, C.; Heinze, M.; Cordes, J.; Mühlbauer, B.; Rüther, E.; Timm, J.; Gründer, G.; Juckel, G. Assessment of psychosocial functioning in a large cohort of patients with schizophrenia. Psychiatr. Q., 2021, 92(1), 177-191. doi: 10.1007/s11126-020-09773-y PMID: 32519208
  37. Schaub, D.; Brüne, M.; Jaspen, E.; Pajonk, F.G.; Bierhoff, H.W.; Juckel, G. The illness and everyday living: Close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261(2), 85-93. doi: 10.1007/s00406-010-0122-1 PMID: 20652295
  38. Suttajit, S.; Arunpongpaisal, S.; Srisurapanont, M.; Thavichachart, N.; Kongsakon, R.; Chantakarn, S.; Chantarasak, V.; Jariyavilas, A.; Jaroensook, P.; Kittiwattanagul, K.; Nerapusee, O. Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains? Neuropsychiatr. Dis. Treat., 2015, 11, 2471-2477. doi: 10.2147/NDT.S88085 PMID: 26491325
  39. Hakulinen, C.; McGrath, J.J.; Timmerman, A.; Skipper, N.; Mortensen, P.B.; Pedersen, C.B.; Agerbo, E. The association between early-onset schizophrenia with employment, income, education, and cohabitation status: Nationwide study with 35 years of follow-up. Soc. Psychiatry Psychiatr. Epidemiol., 2019, 54(11), 1343-1351. doi: 10.1007/s00127-019-01756-0 PMID: 31456027

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers